Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

(Oral) enoximone in asthma

Jan Beute
ERJ Open Research 2020 6: 00319-2020; DOI: 10.1183/23120541.00319-2020
Jan Beute
ZH Rivierenland, Tiel, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: beute.almere@gmail.com
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

PDE-3 inhibitors appear to have a large therapeutic value in asthma treatment; this letter provides some of the insights acquired in recent research https://bit.ly/33D9Dgd

To the Editor:

The Enoximone in status asthmaticus letter [1] referenced our case series from the Netherlands wherein intravenous enoximone (Perfan, Carinopharm, Germany) reversed status asthmaticus in eight patients [2]. Schulz et al. [1] end their letter with the statement that further research is called for; this correspondence is to indicate that research has been carried out and is still ongoing.

Recently, Sobhy et al. [3] confirmed our case series with a successful clinical trial, which was performed in Egypt, using the phosphodiesterase (PDE)-3 inhibitor milrinone. We would like to report we are currently treating 12 children and 51 adults (outpatients) with oral enoximone (Perfan) in addition to standard therapy, in the context of investigational use, in search of effectiveness [4]. Enoximone very swiftly and markedly improved difficult-to-treat asthma, as well as reduced steroid and β2-agonist drugs in 47 of the adult patients, and in 11 of the 12 children. Enoximone in oral form is used to reduce pulmonary arterial pressure by relaxing vascular smooth muscle and it has been used in paediatric post-operative heart failure since 2005 [5, 6]. Our average oral doses are 0.0625–0.125 mg·kg−1, which is 1–6 mg per day for children and 5–15 mg per day for adults; some of them take the drug only two or three times per week. In the Netherlands physicians are allowed to treat their patients with drugs that are not indicated/registered for a particular disease, provided dosage, results and side-effects are closely monitored. We contacted the Dutch Inspection for Health Care and Youth regarding our add-on use of enoximone.

Enoximone is a selective PDE-3 inhibitor; it causes an increase in cyclic adenosine monophosphate (cAMP) and in cyclic guanosine monophosphate (cGMP) in the cell, inhibiting entry of calcium ions, resulting in relaxation and subsequent bronchodilatation. Recently published papers show that enoximone has anti-inflammatory properties due to its effect on pro-inflammatory cytokines and inhibits primary human mast cell degranulation, thus reducing inflammation [7, 8]. It also improves the mucosal barrier function, preventing vascular leakage, causing, in underlying cases, oedema, and is effective in reducing granulocyte-macrophage colony-stimulating factor, interleukin (IL)-6 and tumour necrosis factor (TNF)-α production of epithelial cell cultures that boost an allergic immune response. Enoximone has been shown to be as effective as an anti-pro-inflammatory (IL-6 and TNFα) as methylprednisolone and has the extra benefit of a superior haemodynamic response in patients undergoing cardiopulmonary bypass surgery [9]. This observation indicates that we have a potentially very effective anti-asthma drug. Safety studies in the past illustrate that “low-dose” enoximone, 50 mg orally 3 times a day (n=1854), proved to be “safe” (placebo level) in patients with advanced heart failure [10]; our dosage is 10–30 times less. The drug dosage is based on the lowest effective dose and holds a relatively safe profile.

Enoximone appears to be the first new anti-asthma drug for decades that can be used as a (rescue) medication in all phases of asthma.

We will continue to closely observe our asthmatic patients who (with parents) are highly motivated to continue enoximone add-on therapy because of its immediate and beneficiary effect.

Footnotes

  • Conflict of interest: Breakthrough Medical Research b.v., of which J. Beute is one of the managing directors, has a patent WO 2015/160249 and/or PCT/NL2015/050246 pending, and a patent US15/303,871 issued and J. Beute is a shareholder in Beute Medical Flow b.v., which holds a majority interest in Breakthrough Medical Research b.v.

  • Received May 27, 2020.
  • Accepted June 2, 2020.
  • Copyright ©ERS 2020
http://creativecommons.org/licenses/by-nc/4.0/

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Schulz O,
    2. Wiesner O,
    3. Welte T, et al.
    Enoximone in status asthmaticus. ERJ Open Res 2020; 6: 00367-2019doi: 10.1183/23120541.00367-2019.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Beute J
    . Emergency treatment of status asthmaticus with enoximone. Br J Anaesth 2014; 112: 1105–1108. doi:10.1093/bja/aeu048
    OpenUrlCrossRefPubMed
  3. ↵
    1. Sobhy A,
    2. Eldin DMK,
    3. Zaki HV
    . The use of milrinone versus conventional treatment for the management of life-threatening bronchial asthma. Open Anesthesiol J 2019; 13: 12–17.
    OpenUrl
  4. ↵
    1. Harari S
    . Randomised controlled trials and real-life studies: two answers for one question. Eur Respir Rev 2018; 27: 180080https://doi.org/10.1183/16000617.0080-2018.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Enoximone for pulmonary hypertension
    1. Medicines for Children
    . Enoximone for pulmonary hypertension. 2018. www.medicinesforchildren.org.uk/enoximone-pulmonary-hypertension
  6. ↵
    1. Furck AK,
    2. Bentley S,
    3. Bartsota M, et al.
    Oral enoximone as an alternative to protracted intravenous medication in severe pediatric myocardial failure. Pediatr Cardiol 2016; 37: 1297–1301. doi:10.1007/s00246-016-1433-4
    OpenUrl
  7. ↵
    1. Beute J,
    2. Ganesh K,
    3. Nastiti H, et al.
    PDE3 inhibition reduces epithelial mast cell numbers in allergic airway inflammation and attenuates degranulation of basophils and mast cells. Front Pharmacol. 2020; 11: 470doi: 10.3389/fphar.2020.00470.
    OpenUrl
  8. ↵
    1. Beute J,
    2. Lukkes M,
    3. Koekoek EP, et al.
    A pathophysiological role of PDE3 in allergic airway inflammation. JCI Insight 2018; 3: e94888. doi:10.1172/jci.insight.94888
    OpenUrl
  9. ↵
    1. Santarpino G,
    2. Caroleo S,
    3. Onorati F, et al.
    Inflammatory response to cardiopulmonary bypass with enoximone or steroids in patients undergoing myocardial revascularization: a preliminary report study. Int J Clin Pharmacol Ther 2009; 47: 78–88. doi:10.5414/CPP47078
    OpenUrlCrossRefPubMed
  10. ↵
    1. Metra M,
    2. Eichhorn E,
    3. Abraham WT, et al.
    Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J 2009; 30: 3015–3026. doi:10.1093/eurheartj/ehp338
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Vol 6 Issue 4 Table of Contents
ERJ Open Research: 6 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
(Oral) enoximone in asthma
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
(Oral) enoximone in asthma
Jan Beute
ERJ Open Research Oct 2020, 6 (4) 00319-2020; DOI: 10.1183/23120541.00319-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
(Oral) enoximone in asthma
Jan Beute
ERJ Open Research Oct 2020, 6 (4) 00319-2020; DOI: 10.1183/23120541.00319-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • Pulmonary pharmacology and therapeutics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Interpreting lung oscillometry results
  • Interpreting lung oscillometry results
  • It is time to end our love affair with SABA in asthma?
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society